Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Parkinson's disease and colorectal cancer risk-A nested case control study.

Boursi B, Mamtani R, Haynes K, Yang YX.

Cancer Epidemiol. 2016 Aug;43:9-14. doi: 10.1016/j.canep.2016.05.007. Epub 2016 May 24.

2.

CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis.

Lu Y, Mo C, Zeng Z, Chen S, Xie Y, Peng Q, He Y, Deng Y, Wang J, Xie L, Zeng J, Li S, Qin X.

PLoS One. 2013 Dec 20;8(12):e84413. doi: 10.1371/journal.pone.0084413. eCollection 2013.

3.

Acetaldehyde and parkinsonism: role of CYP450 2E1.

Vaglini F, Viaggi C, Piro V, Pardini C, Gerace C, Scarselli M, Corsini GU.

Front Behav Neurosci. 2013 Jun 21;7:71. doi: 10.3389/fnbeh.2013.00071. eCollection 2013.

4.

Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Cannon JR, Greenamyre JT.

Neurobiol Dis. 2013 Sep;57:38-46. doi: 10.1016/j.nbd.2012.06.025. Epub 2012 Jul 7. Review.

5.

Contributions of human enzymes in carcinogen metabolism.

Rendic S, Guengerich FP.

Chem Res Toxicol. 2012 Jul 16;25(7):1316-83. doi: 10.1021/tx300132k. Epub 2012 May 10. Review.

6.

Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U.

JAMA. 2008 May 28;299(20):2423-36. doi: 10.1001/jama.299.20.2423. Review.

7.

Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.

Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed SB, Chouchane L.

BMC Cancer. 2008 Apr 18;8:109. doi: 10.1186/1471-2407-8-109.

8.

The genetic basis of Parkinson's disease.

Foltynie T, Sawcer S, Brayne C, Barker RA.

J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):363-70. Review.

9.

Candidate gene case-control association studies: advantages and potential pitfalls.

Daly AK, Day CP.

Br J Clin Pharmacol. 2001 Nov;52(5):489-99. Review.

10.

The aetiology of idiopathic Parkinson's disease.

Ramsden DB, Parsons RB, Ho SL, Waring RH.

Mol Pathol. 2001 Dec;54(6):369-80. Review.

11.

Detecting low penetrance genes in cancer: the way ahead.

Houlston RS, Tomlinson IP.

J Med Genet. 2000 Mar;37(3):161-7. Review.

12.

Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Hirvonen A.

Environ Health Perspect. 1999 Feb;107 Suppl 1:37-47. Review.

Supplemental Content

Support Center